Functionally, we found that silencing of GBP1 inhibited EGFRvIII-driven glioblastoma cell growth in vitro and in vivo, suggesting GBP1 is a potential therapeutic target in EGFRvIII-driven tumor growth. The gene discussed is GBP1; the disease is glioblastoma.